Related Experiment Video

Updated: Nov 15, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K

New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy

Marina Bury1, Benjamin Le Calvé2, Gerardo Ferbeyre3

  • 1De Duve Institute, UCLouvain, 1200 Brussels, Belgium.

Trends in Cell Biology
|March 7, 2021
PubMed

Insights

New research identifies ribosomal protein-inhibiting CDKs (RPICs) as a third class of cell cycle regulators. These RPICs, linked to tumor suppression and cellular senescence, offer novel therapeutic targets for cancer and age-related diseases.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Cyclins and cyclin-dependent kinases (CDKs) regulate cell cycle progression.
  • CDK activity is modulated by CDK inhibitors (CKIs), including CIP/KIP and INK families.
  • Cellular senescence is a tumor-suppressive cell cycle arrest linked to aging and cancer.

Purpose of the Study:

  • To review the discovery and significance of ribosomal protein-inhibiting CDKs (RPICs) as a novel CKI class.
  • To explore the role of RPICs in cellular senescence and cancer.
  • To discuss emerging therapeutic strategies targeting CDK activity for cancer and senescence-associated pathologies.

Main Methods:

  • Literature review of recent studies on RPICs, cell cycle regulation, senescence, and cancer.
  • Analysis of the accumulation and downregulation patterns of RPICs in senescent and cancerous cells.
  • Synthesis of information on novel therapeutic approaches targeting CDK pathways.

Main Results:

  • RPICs represent a third distinct family of CDK inhibitors.
  • RPICs accumulate in senescent cells due to reduced rRNA biogenesis.
  • RPICs are frequently downregulated in human cancers, suggesting tumor-suppressive roles.

Conclusions:

  • RPICs are crucial regulators in cellular senescence and possess tumor-suppressive functions.
  • Targeting CDK activity, particularly RPICs, presents promising avenues for precision medicine in oncology and senescence-related diseases.
  • Further research into the tumor-suppressor functions of RPICs and other ribosomal proteins is warranted.
Keywords:
CDKCDK regulatorsRPICcell cyclecyclinribosomal proteins

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.1K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
117.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.6K